Goldberg
Law PC (www.Goldberglawpc.com)
announces that a class action lawsuit has been filed against Clovis
Oncology, Inc. (“Clovis” or the “Company”) (NASDAQ: CLVS).
Investors who purchased or otherwise acquired shares between October 31,
2013 and November 13, 2015, inclusive (the “Class Period”), are
encouraged to contact the Firm in advance of the January 19, 2016, lead
plaintiff motion deadline.
If you are a shareholder who suffered a loss during the Class Period, we
advise you to contact Michael
Goldberg or Brian Schall,
of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey,
CA 90292, at 800-977-7401, to discuss your rights without cost to you.
You can also reach us through the firm’s website at http://www.Goldberglawpc.com,
or by email at info@goldberglawpc.com.
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If you
choose to take no action, you can remain an absent class member.
According to the complaint, the Company made misleading statements to
investors and/or failed to disclose that: (a) the New Drug Application
(“NDA”) that Clovis submitted to the FDA for rociletinib contained
immature data sets; (b) Clovis’ Breakthrough Therapy designation
submission contained immature data set based primarily on unconfirmed
responses; (c) Clovis presented interim data publicly and at medical
meetings that included a data set based primarily on unconfirmed
responses; (d) as the efficacy data matured, the number of patients with
an unconfirmed response who converted to a confirmed response was lower
than expected; (e) as a result of the foregoing, Clovis’ NDA was likely
to be delayed and/or rejected by the FDA; and (f) Clovis was in
possession of data during its third-quarter conference call held on
November 5, 2015, which demonstrated that the confirmed rociletinib
response rate is lower than what was previously disclosed.
If you have any questions concerning your legal rights in this case,
please immediately contact Goldberg Law PC at 800-977-7401, via email at info@goldberglawpc.com,
or visit our website at Goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and specializes
in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151123006385/en/
Copyright Business Wire 2015